ABSTRACT
Objectives Prefilled syringes (PFS) may offer clinical and economic advantages to conventional parenteral medication delivery methods (vials and ampoules). The benefits of converting from vials and ampoules to PFS have been elucidated in previous drug-specific economic models; however, these models have limited generalizability to different drugs, health care settings and other countries. This study aims to (1) present a comprehensive economic model to assess the impact of switching from vials to PFS delivery, and (2) illustrate the model’s utility by highlighting important features of shifting from vials to PFS through two case studies.
Methods The economic model estimates the potential benefit of switching to PFS associated with four key outcomes: preventable adverse drug events (pADE), preparation time, unused drug, and cost of supplies. Model reference values were derived from existing peer-reviewed literature sources. The user inputs specific information related to the department, drug, and dose of interest can change reference values.
Two hypothetical case studies are presented to showcase model utility. The first concerns a cardiac intensive care unit in the United Kingdom administering 30 doses of 1mg/10mL atropine/day. The second concerns a COVID-19 intensive care unit in France that administers 30 doses of 10mg/25mL ephedrine/day.
Results Total cost savings per hospital per year, associated with reductions in pADEs, unused drugs, drug cost and cost of supplies were £34,829 for the atropine example and €108,565 for the ephedrine example. Annual preparation time decreased by 371 and 234 hours in the atropine and ephedrine examples, respectively.
Conclusions The model provides a generalizable framework with customizable inputs, giving hospitals a comprehensive view of the clinical and economic value of adopting PFS. Despite increased costs per dose with PFS, the hypothetical case studies showed notable reductions in medication preparation time and a net budget savings owing to fewer pADEs and reduced drug wastage.
KEY MESSAGES
Globally, most parenteral medications are supplied via injection with medication dispensed from vials and ampoules, despite evidence that such formats result in unused drug, increase risk of preventable adverse drug events, significant hospital staff time to prepare and use of extra supplies.
Prefilled syringes address the shortcomings of these conventional parenteral medication delivery methods, with benefits for patients, healthcare delivery systems, and hospitals.
A novel economic model was developed to estimate the holistic budget impact of switching from vials and/or ampoules to prefilled syringe medication delivery formats for acute care hospital settings.
Results from two hypothetical case studies illustrate an overall cost offset despite higher prices of ready-to-administer formats with prefilled syringes compared to conventional delivery methods.
Competing Interest Statement
Corporate sponsored research or other substantive relationships: MJP received grants and honoraria from various pharmaceutical companies, inclusive of those interested in the topic of this manuscript MW, HG, AT and TE are employees of Becton, Dickinson and Company (BD). Alkemi LLC received consultancy fees to advise on study design, data analysis and interpretation.
Funding Statement
This study was funded by Becton, Dickinson and Company (BD)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
